Stratatech receives $247 million contract to develop skin product. Stratatech will use the contract money to fund a final phase clinical trial for its flagship StrataGraft product, which is delivered to users frozen, giving it a shelf life of about a year, Allen-Hoffmann said. Stratatech is also developing a large pipeline of enhanced human skin products, including an anti-infective skin, a skin that helps grow new blood vessels underneath it and an anti-tumor skin for patients who have had certain skin cancers.
“Stratatech is an excellent example of how far we’ve come in cell-based therapies and tissue regeneration, and how close we are to widespread use of these strategies for patients who don’t have other options,” Bill Murphy said. Read full Article